SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study

Background In ambulatory patients with cancer with asymptomatic or pauci-symptomatic SARS-CoV-2 infection, the safety of targeted therapies (TTs), chemotherapy (CT) or immune checkpoint inhibitors (ICIs) therapy is still unknown.Material and methods From the start of the first epidemic wave of SARS-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paolo Antonio Ascierto, Eliana Rulli, Anna Cecilia Bettini, Maria Grazia Vitale, Carlo Alberto Tondini, Matilde De Luca, Barbara Merelli, Mario Mandala, Sharon Nahm, Paul Lorigan, Andrea Bianchetti, Lucia Bonomi, Giorgia Negrini, Andrea Di Croce
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2021
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/5d142b23383c4287b8f38875db6c9331
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5d142b23383c4287b8f38875db6c9331

Ejemplares similares